Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054497 | 0.90 | — | — | |
| SCHEMBL30515072 | 0.85 | CA1 (0.33) | — | |
| SCHEMBL25334504 | 0.85 | MME (0.30) | — | |
| SCHEMBL3685260 | 0.80 | MMP8 (0.33) | DGAT1 | |
| SCHEMBL4124393 | 0.79 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL25335990 | 0.78 | SLC1A3 (0.30) | — | |
| SCHEMBL234361 | 0.78 | MMP8 (0.41) | DGAT1PTPRBTSHRKCNN4 | |
| SCHEMBL10747276 | 0.73 | — | — | |
| SCHEMBL3686093 | 0.71 | MEN1 (0.41) | TSHR | |
| SCHEMBL809243 | 0.71 | DGAT1 (0.40) | DGAT1PTPRBTSHRKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4469447-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146989-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-2060557-B1 | Intermediate compounds useful to prepare dolasetron | INKE SA (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| US-7858821-B2 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2010-12-28 | — | — | US | disclosed |
| EP-2060557-A1 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060557-A1 | Intermediate compounds useful to prepare dolasetron | INKE, S.A. (ES) | 2009-05-20 | — | — | EP | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | INKE, S.A. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124807-A1 | INTERMEDIATE COMPOUNDS USEFUL TO PREPARE DOLASETRON | DHPS, ALG8, DDOST | DGAT1 1769/4885PTPRB 4298/4885TSHR 4262/4885 |
| US-20250171432-A1 | COMPOUNDS AND METHODS OF USE | ABCG2, F12, CYP2C9 | DGAT1 3906/4885PTPRB 3887/4885TSHR 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.